Integrated Filing — IndAS



General information about company
Scrip Code 524470
NSE Symbol SYNCOMF
MSEI Symbol NOTLISTED
ISIN INE312C01025
Name of company SYNCOM FORMULATIONS (INDIA) LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 08-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 02-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 08-Aug-2025   16:00:00
End date and time of board meeting 08-Aug-2025   16:45:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party?
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.
Whether the company is a high value debt listed entity according to regulation 15 (1A)?
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?
Latest Date on which RPT policy is updated
Indicate Company website link for updated RPT policy of the Company
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 1165469000
Other income 60197000
Total income 1225666000
2 Expenses
(a) Cost of materials consumed 596130000
(b) Purchases of stock-in-trade 156193000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -61639000
(d) Employee benefit expense 159544000
(e) Finance costs 2374000
(f) Depreciation, depletion and amortisation expense 13400000
(f) Other Expenses
1 Other Expenses 157494000 157494000
Total other expenses 157494000
Total expenses 1023496000
3 Total profit before exceptional items and tax 202170000
4 Exceptional items 413000
5 Total profit before tax 202583000
6 Tax expense
7 Current tax 43160000
8 Deferred tax 2130000
9 Total tax expenses 45290000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 157293000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 157293000
17 Other comprehensive income net of taxes 40384000
18 Total Comprehensive Income for the period 197677000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 940000000
Face value of equity share capital 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.21
Diluted earnings (loss) per share from continuing operations 0.21
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.21
Diluted earnings (loss) per share from continuing and discontinued operations 0.21
24 Debt equity ratio 0
25 Debt service coverage ratio 0
26 Interest service coverage ratio 0
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceuticals Drugs and Formulations 1206252000 1206252000
2 Trading of Commodities 10456000 10456000
3 Renting of Properties 8958000 8958000
Total Segment Revenue 1225666000
Less: Inter segment revenue 0 0
Revenue from operations 1225666000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceuticals Drugs and Formulations 196052000 196052000
2 Trading of Commodities 135000 135000
3 Renting of Properties 8357000 8357000
Total Profit before tax 204544000
i. Finance cost 2374000 2374000
ii. Other Unallocable Expenditure net off Unallocable income 0 0
Profit before tax 202170000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceuticals Drugs and Formulations 3930209000 3930209000
2 Trading of Commodities 25918000 25918000
3 Renting of Properties 473344000 473344000
Total Segment Asset 4429471000 4429471000
Un-allocable Assets 0 0
Net Segment Asset 4429471000 4429471000
4 Segment Liabilities
Segment Liabilities
1 Pharmaceuticals Drugs and Formulations 818583000 818583000
2 Trading of Commodities 836000 836000
3 Renting of Properties 13336000 13336000
Total Segment Liabilities 832755000 832755000
Un-allocable Liabilities 0 0
Net Segment Liabilities 832755000 832755000
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) Notesttttt nThe above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 08 08 2025tttt nThese above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to timetttt nThe company is operating in 3 segments A Pharmaceuticals Drugs and Formulations B Trading of Commodities C Renting of Property particulars of segment wise results are given as required.tttt nAs required under Regulation 33 of SEBI LODR Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June 2025. The report does not have any impact on the above results and notes which needs explanationtttt nPrevious period figures have been regrouped reclassified wherever necessary to confirm to this period classification n



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss 40384000 40384000
Total Amount of items that will be reclassified to profit and loss 40384000
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 40384000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Sanjay Mehta & Associates Yes 31-Mar-2027